Answer:
The development in the field of genetic engineering allowed the production of insulin in E. coli and yeast, which have been approved for therapeutic applications in human by FDA [14,15]. Nowadays, recombinant human insulin is mainly produced either in E. coli or Saccharomyces cerevisiae.
